Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance, Nature, vol.18, issue.7262, pp.399-401 ,
DOI : 10.1038/nature08309
The availability od direct acting antivirals in 2012 : a french model based analysis of the increased number of patients traeted for chronic HCV infection, Gut, 2011. ,
122 HCV BURDEN IN EUROPE: IMPACT OF NATIONAL TREATMENT PRACTICES ON FUTURE HCV-RELATED MORBIDITY AND MORTALITY THROUGH A MODELING APPROACH, Journal of Hepatology, vol.54, p.54 ,
DOI : 10.1016/S0168-8278(11)60124-4
Impact of steatosis on progression of fibrosis in patients with mild hepatitis C, Hepatology, vol.34, issue.Suppl 1, pp.82-89, 2005. ,
DOI : 10.1002/hep.20519
EASL Clinical Practice Guidelines: Management of hepatitis C virus infection, 2011. ,
Peg interferonalfa?2a plus ribavirin for chronic hepatitis C in a real life setting : the Hepatys French cohort, 20032007. ,
Effect of HCV RNA suppression during peginterferon alfa?2a maintenance therapy on clinical outcomes in the HALT?C trial. 137:1986?94. effective in patients with hepatitis C who failed interferon alfa/ribavirin therapy, pp.1618-1646 ,
The effects of interferon alfa 2b in combination with ribavirin on health related quality of life and work productivity, J Hepatology, 2001. ,
Impact of Ribavirin Dose Reductions in Hepatitis C Virus Genotype 1 Patients Completing Peginterferon Alfa-2a/Ribavirin Treatment, Clinical Gastroenterology and Hepatology, vol.5, issue.1, pp.124-133 ,
DOI : 10.1016/j.cgh.2006.10.008
Adherence to combination therapy enhances sustained response in genotype?1?infected patients with chronic hepatitis C. Gastroenterolgy, 2002. ,
Telaprevir and Peginterferon with or without Ribavirin for Chronic HCV Infection, New England Journal of Medicine, vol.360, issue.18, pp.1839-50 ,
DOI : 10.1056/NEJMoa0807650
URL : https://hal.archives-ouvertes.fr/inserm-00385235
Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa-2b and ribavirin in treatment-naive patients with genotype 1 hepatitis C infection (SPRINT-1): an open-label, randomised, multicentre phase 2 trial, The Lancet, vol.376, issue.9742, pp.705-721 ,
DOI : 10.1016/S0140-6736(10)60934-8
ADVANCE Study Team. Telaprevir for previously untreated chronic hepatitis C virus infection, pp.2405-2421 ,
Boceprevir for Untreated Chronic HCV Genotype 1 Infection, New England Journal of Medicine, vol.364, issue.13, pp.1195-206 ,
DOI : 10.1056/NEJMoa1010494
URL : https://hal.archives-ouvertes.fr/hal-00867494
Telaprevir substantially improved SVR rates accross all IL28B genotypes in the advance trial, p.543 ,
IL28B polymorphisms predicts virological response in patients with hepatitis C genotype 1 treated with boceprevir combination therapy, p.6 ,
Telaprevir for Previously Treated Chronic HCV Infection, New England Journal of Medicine, vol.362, issue.14, pp.1292-303 ,
DOI : 10.1056/NEJMoa0908014
REALIZE Study Team Telaprevir for retreatment of HCV infection, pp.2417-2445 ,
Boceprevir for Previously Treated Chronic HCV Genotype 1 Infection, New England Journal of Medicine, vol.364, issue.13, pp.1207-1224 ,
DOI : 10.1056/NEJMoa1009482
7 BOCEPREVIR IN ADDITION TO STANDARD OF CARE ENHANCED SVR IN HEPATITIS C VIRUS (HCV) GENOTYPE-1 WITH ADVANCED FIBROSIS/CIRRHOSIS: SUBGROUP ANALYSIS OF SPRINT-2 AND RESPOND-2 STUDIES, Journal of Hepatology, vol.54, p.4 ,
DOI : 10.1016/S0168-8278(11)60009-3
Predictors of virologic response with telaprevir?based combination treatment in HCV genotype 1?infected patients with prior peg?ifn/ribavirin failure : post?hoc analysis of the phase III REALIZE study, p.32 ,
Similar SVR rates in IL28B CC, CT or TT prior relapser, partial or null?responder patients treated with telaprevir/peg? IFN/ribavirin : retrospective analysis of the REALIZE study, p.6 ,
Anemia has no effect on efficacy outcomes in treatment?naive patients who received telaprevir?based regimen in ADVANCE and ILLUMINATE phase 3 studies, p.195 ,
Anemia during treatment with peginterferon alfa?2B/ribavirin with or without boceprevir is associated with higherSVR rates : analysis of previously untreated and previous?treatment?failure patients, p.194 ,
Epoetin alfa maintains ribavirin dose in HCV?infected patients: a prospective, double?blind, randomized controlled study, pp.1302-1313 ,
Résumé du rapport de synthèse N°3, 2011. ,
Budget impact analysis of boceprevir and telaprevir for the treatment of hepatitis C genotype 1 infection, ClinicoEconomics and Outcomes Research, pp.349-359, 2012. ,
Cost-effectiveness of boceprevir or telaprevir for previously treated patients with genotype 1 chronic hepatitis C, Journal of Hepatology, vol.59, issue.4, pp.658-666, 2013. ,
DOI : 10.1016/j.jhep.2013.05.019
Prescription drug database and drug prescribing guide (2012) Disponible sur ,
Boceprevir and telaprevir for the treatment of chronic hepatitis C genotype 1 infection: an indirect comparison meta?analysis, Therapy Clinical Risk Manager, vol.8, pp.105-130 ,
Direct-acting antiviral therapies for hepatitis C genotype 1 infection: a multiple treatment comparison meta-analysis, QJM, vol.106, issue.2, 2012. ,
DOI : 10.1093/qjmed/hcs214
What is the minimum cost per person to cure HCV? 7th IAS Conference on HIV Pathogenesis, Treatment and Prevention, 2013. ,
Efficacy of boceprevir in prior null responders tp Peg?interferon?Ribavirin : the PROVIDE study, p.931 ,